Fresenius Kabi has announced the availability of Levothyroxine Sodium Injection Solution in 100mcg per 5mL, 200mcg per 5mL and 500mcg per 5mL single-dose vials.
The Company already manufactures a lyophilized powder version of Levothyroxine Sodium for Injection, however, the new formulation eliminates the need for reconstitution.
Levothyroxine sodium injection is indicated for the treatment of adult patients with myxedema coma. The product is not recommended as a substitute for oral levothyroxine sodium because the relative bioavailability of levothyroxine sodium injection to oral levothyroxine sodium has not been established and there is a risk of inaccurate dose conversion.
For more information visit Fresenius-Kabi.com.
This article originally appeared on MPR